share_log

Just Three Days Till China Meheco Group Co., Ltd. (SHSE:600056) Will Be Trading Ex-Dividend

Just Three Days Till China Meheco Group Co., Ltd. (SHSE:600056) Will Be Trading Ex-Dividend

距離中國醫藥集團股份有限公司(SHSE:600056)除權交易只有三天
Simply Wall St ·  06/22 21:40

Readers hoping to buy China Meheco Group Co., Ltd. (SHSE:600056) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least two business day to settle. Therefore, if you purchase China Meheco Group's shares on or after the 27th of June, you won't be eligible to receive the dividend, when it is paid on the 27th of June.

希望購買中國醫藥股份有限公司(SHSE:600056)的分紅的讀者們需要儘快採取行動,因爲這隻股票即將進行除息。除息日是公司股權登記日前的一個工作日,亦即公司確定哪些股東有權獲得分紅的日期。除息日的影響是巨大的,因爲無論何時買入或賣出一隻股票,交易都需要至少兩個交易日才能結算。因此,如果您在6月27日或之後購買中國醫藥的股票,當它於6月27日支付分紅時,您將無法獲得分紅。

The company's next dividend payment will be CN¥0.21019 per share. Last year, in total, the company distributed CN¥0.21 to shareholders. Last year's total dividend payments show that China Meheco Group has a trailing yield of 2.0% on the current share price of CN¥10.40. If you buy this business for its dividend, you should have an idea of whether China Meheco Group's dividend is reliable and sustainable. We need to see whether the dividend is covered by earnings and if it's growing.

該公司下一個分紅爲每股人民幣0.21019元。去年,公司總共向股東分配了人民幣0.21元的分紅。去年的總分紅額表明,中國醫藥在當前人民幣10.40元的股票價格下具有2.0%的年度回報率。如果您因分紅而購買這家公司,您需要了解中國醫藥的分紅是否可靠和可持續。我們需要查看分紅是否被盈利覆蓋以及是否在增長。

If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. That's why it's good to see China Meheco Group paying out a modest 34% of its earnings. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Thankfully its dividend payments took up just 46% of the free cash flow it generated, which is a comfortable payout ratio.

如果公司支付的股息比它賺的更多,那麼股息可能變得不可持續,這絕非理想情況。這就是爲什麼看到中國醫藥支付的股息僅佔盈利的適度34%是一個好兆頭。然而,現金流通常比利潤更重要,用於評估股息的可持續性,因此我們應該始終檢查公司是否產生了足夠的現金來支付其股息。值得慶幸的是,它的分紅支付只佔其自由現金流的46%,這是一個舒適的支付比率。

It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

看到股息既有盈利也有現金流的覆蓋是令人鼓舞的。這通常表明股息是可持續的,只要收益沒有急劇下降。

Click here to see how much of its profit China Meheco Group paid out over the last 12 months.

單擊此處,了解中國醫藥過去12個月的利潤分配情況。

historic-dividend
SHSE:600056 Historic Dividend June 23rd 2024
SHSE:600056歷史分紅6月23日2024年

Have Earnings And Dividends Been Growing?

收益和股息一直在增長嗎?

When earnings decline, dividend companies become much harder to analyse and own safely. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. China Meheco Group's earnings per share have fallen at approximately 9.7% a year over the previous five years. When earnings per share fall, the maximum amount of dividends that can be paid also falls.

當收益下降時,分紅公司變得更加難以分析和安全持有。如果業務進入低谷並且分紅被削減,公司的價值可能會急劇下降。中國醫藥的每股收益在過去五年中每年下降約9.7%。當每股收益下降時,可以支付的最大股息金額也會下降。

Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. In the last 10 years, China Meheco Group has lifted its dividend by approximately 7.4% a year on average.

許多投資者會通過評估股息支付在相當長一段時間內的變化來評估公司的股息表現。在過去的10年中,中國醫藥的股息平均每年增長約7.4%。

The Bottom Line

還有一件事需要注意的是,我們已經確定了上海醫藥的2個警告信號,了解這些信號應該成爲你的投資過程的一部分。

From a dividend perspective, should investors buy or avoid China Meheco Group? Earnings per share are down meaningfully, although at least the company is paying out a low and conservative percentage of both its earnings and cash flow. It's definitely not great to see earnings falling, but at least there may be some buffer before the dividend needs to be cut. In summary, while it has some positive characteristics, we're not inclined to race out and buy China Meheco Group today.

從分紅的角度來看,投資者應該買入還是避開中國醫藥?每股收益顯著下降,儘管公司的盈利和現金流支付比率都低且保守,這絕非好事。收益下降肯定不是什麼好現象,但至少在削減分紅之前可能有一些緩衝。總之,儘管它具有一些積極的特點,但我們並不傾向於今天就買入中國醫藥。

While it's tempting to invest in China Meheco Group for the dividends alone, you should always be mindful of the risks involved. We've identified 3 warning signs with China Meheco Group (at least 1 which is a bit concerning), and understanding them should be part of your investment process.

雖然單純爲了分紅而投資中國醫藥很有吸引力,但您應該始終注意所涉及的風險。我們已經確定了中國醫藥的3個警示信號(至少有1個令人擔憂),了解它們應該成爲您的投資過程的一部分。

Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.

一般來說,我們不建議僅僅購買第一個股息股票。下面是一個經過策劃的有趣的、股息表現良好的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論